Abrocitinib as a novel treatment for lichen sclerosus

Chengbei Bao; Qiuyun Xu; Zhixun Xiao; Haiqing Wang; Renwei Luo; Bo Cheng; Chao Ji; Ting Gong

doi:10.1093/bjd/ljad129

Abrocitinib as a novel treatment for lichen sclerosus

Br J Dermatol. 2023 Jul 7;189(1):136-138. doi: 10.1093/bjd/ljad129.

Authors

Chengbei Bao^{1

2

3}, Qiuyun Xu^{1

2

3}, Zhixun Xiao^{1

2

3}, Haiqing Wang^{1

2

3}, Renwei Luo^{1

2

3}, Bo Cheng^{1

2

3}, Chao Ji^{1

2

3}, Ting Gong⁴

Affiliations

¹ Department of Dermatology.
² Fujian Dermatology and Venereology Research Institute.
³ Key Laboratory of Skin Cancer of Fujian Higher Education Institutions.
⁴ Central Laboratory, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

PMID: 37093680
DOI: 10.1093/bjd/ljad129

No abstract available

MeSH terms

Female
Humans
Lichen Sclerosus et Atrophicus* / drug therapy
Pyrimidines
Sulfonamides
Vulvar Lichen Sclerosus* / drug therapy

Substances

abrocitinib
Pyrimidines
Sulfonamides

MeSH terms

Substances

Grants and funding